Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > New Press Release - Ventripoint Announces Date and Timing for Release of Q3 2023 Financial Results and Webinar
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1520)
•••
Comment by Pandoraon Nov 25, 2023 8:32pm
100 Views
Post# 35753146

RE:New Press Release - Ventripoint Announces Date and Timing for Release of Q3 2023 Financial Results and Webinar

RE:New Press Release - Ventripoint Announces Date and Timing for Release of Q3 2023 Financial Results and Webinar
I'm always a little apprehensive when a company starts their message off by saying  "we are pleased to present..."

Sometimes there is reason to be "pleased" but over the years there have never been reasons to be pleased but they always start "we are pleased to present......."

Hopefully this time around there is really content in there that makes them "pleased". Otherwise they should just say "we will be presenting......." and leave it at that.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities